Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07914855
PHASE2

Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

Sponsor: National Cancer Institute (NCI)

View on ClinicalTrials.gov

Summary

This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread despite androgen deprivation therapy (castration-resistant). The growth and survival of prostate tumor cells often depends on testosterone. Androgen deprivation therapy blocks the use of testosterone by the tumor cells. Although most tumors respond to androgen deprivation therapy at first, nearly all eventually progress to a castration-resistant state. Enzomenib, a menin inhibitor, targets and blocks menin, a protein that plays a role in the survival and growth of tumor cells.

Official title: A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2027-02-26

Completion Date

2029-01-04

Last Updated

2026-11-12

Healthy Volunteers

No

Interventions

DRUG

Antiandrogen Therapy

Given usual androgen deprivation therapy

PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT, FDG PET/CT, and PSMA PET/CT

DRUG

Enzomenib

Given PO

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG PET/CT

OTHER

Fludeoxyglucose F-18

Given FDG

PROCEDURE

PSMA PET Scan

Undergo PSMA PET/CT